Sodelglitazar

Sodelglitazar, formerly known as GW 677954, is a thiazole PPARδ receptor agonist developed by GlaxoSmithKline.[2] While it is primarily active at the PPARδ receptor, it is considered a pan agonist with activity at PPARα and PPARγ receptors.[3]

Sodelglitazar
Clinical data
Pregnancy
category
  • N/A
ATC code
  • None
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC23H21F4NO3S2
Molar mass499.54 g·mol−1
3D model (JSmol)

Safety

Phase 2 studies were terminated prior to completion due to safety findings in rodent studies.[4]

See also

References
  1. US Patent No. 7105551 "96 dpi image of original patent USPTO 7105551" (PDF). Retrieved 2 Apr 2013.
  2. Liu, X. Y.; Wang, R. L.; Xu, W. R.; Tang, L. D.; Wang, S. Q.; Chou, K. C. (2011). "Docking and molecular dynamics simulations of peroxisome proliferator activated receptors interacting with pan agonist sodelglitazar". Protein and Peptide Letters. 18 (10): 1021–1027. doi:10.2174/092986611796378701. PMID 21592078.
  3. Eckhard Ottow, Hilmar Weinmann (2008). Nuclear Receptors as Drug Targets. Wiley. pp. 380–. ISBN 978-3-527-31872-8. Retrieved 2 April 2013.
  4. "A randomised, double-blind, parallel group, placebo-controlled, multicentre study to evaluate the safety, tolerability and efficacy of oral GW677954 capsules 2.5mg, 5mg, 10mg and 20mg a day for 24 weeks in overweight dyslipidaemic subjects" (PDF). GlaxoSmithKline. 2013-09-01.



This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.